TY  - CHAP
M1  - Book, Section
TI  - Superficial Fungal Infections
A1  - Fuller, Kathryn A.
A1  - Schlesselman, Lauren S.
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Bookstaver, P. Brandon
A2  - Lee, Kelly C.
PY  - 2022
T2  - Pharmacotherapy Principles & Practice, 6e
AB  - LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Explain  the  underlying  pathophysiology  of  vulvovaginal  candidiasis  (VVC),  oropharyngeal  candidiasis  (OPC),  esophageal  candidiasis,  and  fungal  skin  infections.Identify  symptoms  of  VVC,  OPC,  esophageal  candidiasis,  and  fungal  skin  infections.Identify  the  desired  therapeutic  outcomes  and  monitoring  parameters  for  resolution  and  safety  for  patients  with  uncomplicated  and  complicated  VVC,  OPC,  esophageal  candidiasis,  and  fungal  skin  infections.Recommend  appropriate  lifestyle  modifications  and  pharmacotherapy  interventions  for  patients  with  VVC,  OPC,  esophageal  candidiasis,  and  fungal  skin  infections.Recognize  when  long-term  suppressive  therapy  is  indicated  for  a  patient  with  VVC.Identify  when  topical  versus  oral  treatment  is  indicated  for  a  patient  with  OPC,  esophageal  candidiasis,  VVC,  and  fungal  skin  infections.Educate  patients  regarding  their  disease  state,  appropriate  lifestyle  modifications,  and  medication  therapy  required  for  effective  treatment  of  VVC,  OPC,  esophageal  candidiasis,  and  fungal  skin  infections.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/09/07
UR  - ppp.mhmedical.com/content.aspx?aid=1187021422
ER  -